In recent years, in association with progress and innovation in the field of pharmaceutical technology, there has been an increasing effort to develop prolonged release dosage forms for many drugs. Correspondingly, a growing number of new prolonged release dosage forms have been submitted for regulatory approval. Prolonged release dosage forms have many advantages in safety and efficacy over im...

The present work deals with the development of a prolonged release matrix tablet readily soluble drug pramipexole. new excipient Kollidon SR (a mixture 80% polyvinyl acetate and 20% polyvinylpyrrolidone) hypromellose K15M were used as polymers to control from selected prototypes. Various polymer concentrations tested achieve stable pH independent pramipexole 0.26 mg over 24 hours; samples prepa...

To the Editor: A recent article by Baron et al. reports the results of a clinical trial (CT) to compare the effectiveness of tapentadol with oxycodone/ naloxone (Ox/Nal) for the treatment of chronic low back pain of neuropathic origin. This study is a remarkable attempt to progress in this area. We argue, however, that it contains several drawbacks that leave open ground for further trials with...

Drug release kinetics plays an important role in determining the mechanism of drug release, which in turn helps in formulating controlled/sustained release formulations.In our study, different concentrations of green tea polyphenols (GTP) were encapsulated into casein nanoparticles which showed a maximum encapsulation efficiency (76.9%) at a GTP concentration of 5 mg/mL. The casein nanopa...

Drug release kinetics plays an important role in determining the mechanism of drug release, which in turn helps in formulating controlled/sustained release formulations.In our study, different concentrations of green tea polyphenols (GTP) were encapsulated into casein nanoparticles which showed a maximum encapsulation efficiency (76.9%) at a GTP concentration of 5 mg/mL. The casein nanopa...

Ropinirole prolonged release is a once-daily, 24-hour formulation of ropinirole, a non-ergot dopamine agonist. It is approved as monotherapy and as an adjunct to levodopa in the treatment of Parkinson's disease (PD). Several potential advantages of ropinirole prolonged release compared to the immediate release formulation include maintaining more consistent dopaminergic activity with steadier p...